Unknown PHASE4 INTERVENTIONAL 1-arm NCT03799692

Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Clinical Trial of Nanoparticle Albumin-Bound Paclitaxel Combined With Carboplatin as Neoadjuvant Chemotherapy in Luminal B/HER-2 Negative Breast Cancer

Sponsor: Fudan University

Conditions HER-2 Negative Breast Cancer

Interventions Chemotherapy

Updated 5 times since 2019 Last updated: Jan 8, 2019 Started: Nov 19, 2018 Primary completion: Mar 30, 2019 Completion: Jul 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HER-2 Negative Breast Cancer and is currently ongoing. Fudan University leads this study, which shows 5 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Feb 2021 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE4
Feb 2019 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fudan University

Data source: Fudan University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China